Isocitrate Dehydrogenase 1 Inhibitor class drugs

2 results

  • tibsovo

    (ivosidenib)
    Servier Pharmaceutical LLC
    TIBSOVO is indicated for treating newly diagnosed acute myeloid leukemia (AML) with an IDH1 mutation, relapsed or refractory AML, relapsed or refractory myelodysplastic syndromes (MDS), and previously treated locally advanced or metastatic cholangiocarcinoma with an IDH1 mutation in adults.
    Medication Details
    Drug Interactions

  • voranigo

    (vorasidenib)
    Servier Pharmaceuticals LLC
    VORANIGO is indicated for treating adults and pediatric patients aged 12 and older with Grade 2 astrocytoma or oligodendroglioma harboring IDH1 or IDH2 mutations, post-surgery (biopsy, sub-total, or gross total resection), as identified by an FDA-approved test.
    Medication Details
    Drug Interactions